Abstract
Introduction: This review provides an overview of the molecular mechanisms and pathways known to enhance development and progression of pancreatic ductal adenocarcinoma (PDAC). Results: Today, the concept that progression of epithelial precursor lesions leads to invasive PDAC as a result of accumulating mutation in K-ras, p16INK4A, p53 and Smad4 is widely accepted. Multiple signaling pathways that PDAC utilizes to acquire its tumorigenic features have been identified. Recent data suggest that reactivated developmental signaling pathways play a role in oncogenesis of PDAC. Furthermore, it is now clear that the tumor microenvironment actively promotes invasion and tumor growth through a complex of interactions of different cellular components. Conclusion: PDAC is still a challenging entity for physicians and scientists. Despite of recent advances in understanding its molecular biology, treatment options remain limited. Distinct tumor stroma interactions and apoptotic resistance lead to frequent failure of current chemotherapy. An early and aggressive tumor infiltration in combination with a late diagnosis prevents successful surgical therapy. Thus, our primary goal remains to translate the increasing knowledge of molecular pathogenesis of this disease into successful therapeutic strategies. Apart from tumor cell biology, the complex interactions of PDAC cells with their microenvironment have to be focus of future molecular research.
Keywords: Pancreatic cancer, pathogenesis, genetics, desmoplasia, signaling pathways
Anti-Cancer Agents in Medicinal Chemistry
Title: An Update on Molecular Research of Pancreatic Adenocarcinoma
Volume: 11 Issue: 5
Author(s): Christian Krautz, Felix Ruckert, Hans-Detlev Saeger, Christian Pilarsky and Robert Grutzmann
Affiliation:
Keywords: Pancreatic cancer, pathogenesis, genetics, desmoplasia, signaling pathways
Abstract: Introduction: This review provides an overview of the molecular mechanisms and pathways known to enhance development and progression of pancreatic ductal adenocarcinoma (PDAC). Results: Today, the concept that progression of epithelial precursor lesions leads to invasive PDAC as a result of accumulating mutation in K-ras, p16INK4A, p53 and Smad4 is widely accepted. Multiple signaling pathways that PDAC utilizes to acquire its tumorigenic features have been identified. Recent data suggest that reactivated developmental signaling pathways play a role in oncogenesis of PDAC. Furthermore, it is now clear that the tumor microenvironment actively promotes invasion and tumor growth through a complex of interactions of different cellular components. Conclusion: PDAC is still a challenging entity for physicians and scientists. Despite of recent advances in understanding its molecular biology, treatment options remain limited. Distinct tumor stroma interactions and apoptotic resistance lead to frequent failure of current chemotherapy. An early and aggressive tumor infiltration in combination with a late diagnosis prevents successful surgical therapy. Thus, our primary goal remains to translate the increasing knowledge of molecular pathogenesis of this disease into successful therapeutic strategies. Apart from tumor cell biology, the complex interactions of PDAC cells with their microenvironment have to be focus of future molecular research.
Export Options
About this article
Cite this article as:
Krautz Christian, Ruckert Felix, Saeger Hans-Detlev, Pilarsky Christian and Grutzmann Robert, An Update on Molecular Research of Pancreatic Adenocarcinoma, Anti-Cancer Agents in Medicinal Chemistry 2011; 11 (5) . https://dx.doi.org/10.2174/187152011795677409
DOI https://dx.doi.org/10.2174/187152011795677409 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeting EGFR in Pancreatic Cancer Treatment
Current Drug Targets Marizomib, a Proteasome Inhibitor for All Seasons: Preclinical Profile and a Framework for Clinical Trials
Current Cancer Drug Targets Herbal Drugs for Diabetic Treatment: An Updated Review of Patents
Recent Patents on Anti-Infective Drug Discovery Aqueous Extract of Argania spinosa L. Fruits Ameliorates Diabetes in Streptozotocin-Induced Diabetic Rats
Cardiovascular & Hematological Agents in Medicinal Chemistry A Comprehensive Review on Chrysin: Emphasis on Molecular Targets, Pharmacological Actions and Bio-pharmaceutical Aspects
Current Drug Targets The Applicability of mTOR Inhibition in Solid Tumors
Current Cancer Drug Targets Inhibition of Topoisomerase I by Anti-Cancer Drug Altered the Endometrial Cyclicity and Receptivity
Current Molecular Medicine The Role of Neutrophils and TH17 Cells in the Immunopathology of Severe Asthmax
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Using Pharmacologic Data to Plan Clinical Treatments for Patients with Peritoneal Surface Malignancy
Current Drug Discovery Technologies Recent Developments in Anti-Cancer Agents Targeting the Ras/Raf/ MEK/ERK Pathway
Recent Patents on Anti-Cancer Drug Discovery High Expression of Human Leukocyte Antigen-G is Associated with a Poor Prognosis in Patients with PDAC
Current Molecular Medicine Gene Therapy Using IL-12 Family Members in Infection, Auto-Immunity, and Cancer
Current Gene Therapy Drug-Delivery Systems of Green Tea Catechins for Improved Stability and Bioavailability
Current Medicinal Chemistry Anticancer Actions of Omega-3 Fatty Acids - Current State and Future Perspectives
Anti-Cancer Agents in Medicinal Chemistry Effect of Antioxidant Extract from Cherries on Diabetes
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Potential Interactions between miRNAs and Hypoxia: A New Layer in Cancer Hypoxia
Anti-Cancer Agents in Medicinal Chemistry Rationale for an Intraperitoneal Gemcitabine Chemotherapy Treatment for Patients with Resected Pancreatic Cancer
Recent Patents on Anti-Cancer Drug Discovery Protein-protein Interfaces Integrated into Interaction Networks: Implications on Drug Design
Current Pharmaceutical Design Near Infrared Receptor-Targeted Nanoprobes for Early Diagnosis of Cancers
Current Medicinal Chemistry Nanomedicines as Cancer Therapeutics: Current Status
Current Cancer Drug Targets